Articles


Research News

Published on 10 September 2021

Biosimilar epoetin for cancer and chemotherapy-induced anaemia in the US

Biosimilars are biological drug products that are highly similar to reference products in analytic features, pharmacokinetics and pharmacodynamics, immunogenicity, safety and efficacy. Biosimilar epoetin received US Food and Drug Administration...

DOI: 10.5639/gabij.2021.1003.015


2.411 views

Pilot Study

Published on 30 August 2021

Use of biologicals in dermatology – following the agreed path or going off-piste? A brief report

Author byline as per print journal: Michael Wilcock, MPhil; Andrew Pothecary, MSc Introduction: Biological medicines are used to treat a range of conditions according to National Institute for Health and...

biologicals, biosimilars, dermatology, psoriasis

DOI: 10.5639/gabij.2021.1003.018


6.085 views

Original Research

Published on 30 August 2021

Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers

Author byline as per print journal: Nishalini Harikrishnan1, BSc; Ka-Liong Tan2, DPhil; Kar Ming Yee3, BPharm; Alia Shaari Ahmad Shukri1, MSc; Nalla Ramana Reddy4, MBBS; Chuei Wuei Leong3, PhD Introduction/Study...

bioequivalence, COX-2 inhibitor, etoricoxib, generics

DOI: 10.5639/gabij.2021.1003.013


8.944 views

Review Article

Published on 27 July 2021

A critical review of substitution policy for biosimilars in Canada

Author byline as per print journal: Professor Philip J Schneider1, MS, FASHP, FASPEN, FFIP; Michael S Reilly2, Esq Canada has approved a total of 36 biosimilars. While the approval of...

Author(s): Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP

biosimilars, Canada, policy, substitution, switching

DOI: 10.5639/gabij.2021.1003.016


8.347 views

Abstracted Scientific Content

Published on 22 June 2021

An IPRP survey of the regulatory requirements for the waiver of in vivo bioequivalence studies of generic medicinal products in certain dosage forms

Submitted: 14 May 2021; Revised: 14 May 2021; Accepted: 3 June 2021; Published online first: 10 June 2021 Medicines regulatory authorities aim to address rising healthcare costs and promote access...

Author(s): Alfredo García Arieta, PhD, Clare Rodrigues

DOI: 10.5639/gabij.2021.1003.019


3.668 views

Review Article

Published on 22 June 2021

Microbiological, scientific and regulatory perspectives of hand sanitizers

Author byline as per print journal: Adjunct Associate Professor Sia Chong Hock, BSc (Pharm), MSc; Tan Ying Ting, BSc Pharm (Hons); Associate Professor Chan Lai Wah, BSc Pharm (Hons), PhD...

effectiveness, hand sanitizers, myths, regulatory framework, safety, standards

DOI: 10.5639/gabij.2021.1003.017


8.905 views

Published on 22 June 2021

2021/2 GaBI Journal Table of Contents

Contents Editor’s Letter What to look forward to in GaBI Journal, 2021, Issue 2 Original Research Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector via simulation Biosimilars in Saudi...

1.644 views

Abstracted Scientific Content

Published on 21 May 2021

Repurposing non-oncology drugs for cancer treatment

Submitted: 15 March 2021; Revised: 17 March 2021; Accepted: 18 March 2021; Published online first: 24 March 2021 Cancer is one of the leading causes of mortality in the world...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2021.1002.011


2.601 views

Editor's Letter

Published on 20 May 2021

What to look forward to in GaBI Journal, 2021, Issue 2

The current pandemic has greatly amplified the already existing disparities in access to health care. Many countries are facing a lack of access to or funding to pay for the...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2021.1002.005


3.010 views

Thank you to reviewers

Published on 09 March 2021

Thank you to reviewers 2020

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

2.609 views

Published on 09 March 2021

2021/1 GaBI Journal Table of Contents

Contents Editor’s Letter First 2021 GaBI Journal issue highlights Original Research Biosimilars – status in July 2020 in 16 countries An assessment of trends in the Iranian pharmaceutical market following...

1.759 views

Editor's Letter

Published on 23 February 2021

First 2021 GaBI Journal issue highlights

The articles in this first issue contain a large volume of useful information on the global development, approval, manufacturing, marketing, and uptake of biosimilars. The first Original Research by Dr...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2021.1001.001


2.694 views